FHD-286
A Phase 1, Multicenter, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286, as Monotherapy or Combination Therapy, in Subjects With Advanced Hematologic Malignancies
Filters
Save & Share
Clear Filters
Location
Explore options near your center - or near your patient's home.
MDS Centers of Excellence
Diagnosis
Purpose of Trial
Filter and find trials based on their purpose.
Risk Level
Enter this patient's risk level (IPSS-R / IPSS-M).
Near Add Your Location
Sort by
Center of Excellence
Memorial Sloan Kettering Cancer Center
New York, NY
- Accepting patients
- Show Principal Investigator
Center of Excellence
- Accepting patients
Center of Excellence
Dana-Farber Cancer Institute
Boston, MA
- Accepting patients
Center of Excellence
- Accepting patients
Center of Excellence
- Accepting patients
Colorado Blood Cancer Institute
Sarah Cannon at Presbyterian/St. Luke's Medical Center (HealthONE)
Denver, CO
- Accepting patients
- Accepting patients
- Show Principal Investigator
509 hidden based on your filters. Show All
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.